Beruflich Dokumente
Kultur Dokumente
www.GlobalPharmacyMeds.to
Your Long-Term Solution to Rising Prescription Drug Costs
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
Q. What is a generic?
A. Drug manufacturers hold patents on the brand-name drugs they make and sell. When
the patent expires, pharmaceutical companies can manufacture a generic, or copy, of the
brand-name and sell it at substantial discounts.
A generic medication has the same dosage, safety, strength, quality, directions,
performance, and intended use as its brand-name counter-part. Before generics are made
available on the market, the manufacturer must prove it has the same active ingredients as
the brand-name and works as effectively. The only differences between generics and their
brand-name counterparts is that generics are less expensive and may look slightly
different (eg. different shape or color), as trademark laws prevent a generic from looking
exactly like the brand-name medication. Generics are less expensive because generic
manufacturers do not have to invest large sums of money to invent a drug.
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
Shipping Policy
Please allow up to 2-3 business days to process your prescriptions in our pharmacy once
we have your completed patient profile and your VALID prescriptions. Once shipped,
postal service times generally range from 5 to 15 business days (N.B.: some locations can
be longer). If you do not receive your order after 15 business days, please call us toll free
at 1-866-799-3435 and Use Discount Code 10786 for help on tracking your package.
Your prescription order is shipped via an expedited mailing service (usually Canada
Post's XpressPost). Delivery confirmation is provided whereby each shipment is assigned
an identification number that can be used to check the delivery status of your order. From
our other global suppliers, orders are shipped through diverse airmail services.
As per the ordering guide agreement, all prescription sales are FINAL and NONREFUNDABLE as GlobalPharmacyMeds.to cannot legally accept or restock orders that
are cancelled or refused after they have left the pharmacy.
Cancellation of orders placed prior to leaving the pharmacy will result in a cancellation
fee of $25. Again orders dispensed cannot be refunded.
Shipping Promotions: Free shipping applies on any order for prescription items above
$299.00 USD (exclusive of shipping fees)! Any order for items that are part of our
International Generic Program and is above $99.00 USD (exclusive of shipping) are also
shipped free!
Shipping Rate: Shipping and handling charges are $ 8.00 USD. per package for
prescription items. The shipping and handling fee ($ 8.00 USD) applies to each parcel,
not prescription. If all your medications fit in one parcel, you will pay one shipping fee.
International Shipping Rates: Shipping and handling charges may vary depending on
the location. Some countries may require an additional $10-$55 over the standard
shipping rate. The shipping and handling fee applies to each parcel, not prescription. If all
your medications fit in one parcel, you will pay one shipping fee.
Shipping time can take longer than the advertised 15 business days and in some instances
can take up to 2 months depending on the nature of your postal service and customs
regulations. Please take the time to verify your country's rules and policies for the
importation of medication.
GlobalPharmacyMeds.to
Refrigerated items: Handling charges are $20.00 USD. per package for prescription
items. The handling fee ($20.00 USD) applies to each parcel, not prescription. If all your
medications fit in one parcel, you will pay one shipping fee. Depending on your location,
we may not be able to ship refrigerated items to you. This is a sample of products that
require refrigerated shipping:
Actimmune
Amoxil (suspension)
Augmentin (suspension)
Avonex Admin Pack
Baygam
Benzamycin (gel)
Benzaclin (gel)
Calcitonin-Salmon
Caverject (vial)
Ceftin (suspension)
Cefzil (suspension)
Cephalexin (suspension)
Cipro (suspension)
Combipatch
Copaxone
DDAVP (tube)
Desmopressin
Duricef (suspension)
Emcyt (capsule)
Enbrel (kit)
Epogen
Fortovase (softgel)
Gamimune (vial)
GlobalPharmacyMeds.to
Genotropin (cartridge)
Havrix (vial)
Humalog
Humatrope (vial)
Humulin
Iletin (vial)
Infergen (vial)
Insulin
Intron A
Kaletra
Lantus
Leukeran
Lorabid (suspension)
Lymerix (vial)
Miacalcin
Muse
Mycostatin (pastilles)
Nystatin
Neupogen (vial)
Norditropin (vial)
Norvir (softgel)
Novolin
Novolog
Nystatin (powder)
Ophthetic (eye drops)
Phenergan
Phospholine Iodide
Procrit
Promethegan (suppository)
Rapamune (solution)
Rebetron
Recombivax
Regranex (gel)
Sandostatin
Suprax
Syprine (capsule)
Thyrolar
Trimox (suspension)
Veetids (suspension)
Velosulin (vial)
VePesid (capsules)
Vibramycin (suspension)
Viroptic (eye drops)
Xalatan (eye drops)
Zithromax (suspension)
An estimated 1.8 million Americans save money by buying drugs from other
countries, especially Canada, which sets price limits as part of its national health
system.
Generics made up 63 percent of prescriptions dispensed in the United States in
2006, up 13 percent from 2005. And these days, the countrys biggest supplier of
prescription drugs, as measured by prescriptions filled, is not a high-profile
American company like Pfizer or Merck. It is Teva Pharmaceutical, a generic
manufacturer based in Israel, according to data from IMS Health, a firm that
tracks the market.
A vast majority of Americans (88 percent) are confident that prescription drugs
made in the United States are safe. In contrast, only 56 percent think that drugs
made in Canada and Europe are safe, and only 14 percent think that drugs made in
China and India are safe. Buy many of the drugs sold in the United States are
made in China and India, according to James Thurber, the director of the Center
for Congressional and Presidential Studies at American University.
According to the national Health Interview Survey, from January through March
2007, 41.9 million persons of all ages (14.2%) were uninsured at the time of the
interview, 52.8 million (17.8%) had been uninsured for at least part of the year
prior to the interview, and 30.6 million (10.3%) had been uninsured for more than
a year at the time of the interview. Also, the percentage of children under the age
of 18 years who were uninsured at the time of the interview was 8.5% in the first
3 months of 2007.
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
Forward
We at GlobalPharmacyMeds.to are proud to include you as one of our valued and
loyal customers. If you have never ordered from us, we thank you for your interest in our
company and hope that we will have the pleasure of counting you as a customer after
browsing this guide. For over three years, thousands of customers have enjoyed the
benefits of purchasing their Canadian prescription medications from a reliable and
trustworthy company. Throughout the years, we have aimed at providing you with some
of the most competitive prices on all Canadian prescription medications as well as with
the best customer service and support the industry has to offer.
We realize that over the past couple of years there has been an increase in the prices of
your Canadian medications despite our very best efforts. The release of this information
booklet marks the advent of a new initiative undertaken to maintain our competitive
pricing and high quality services you have come to expect from our company. It is a
testament of our renewed promise to fulfill our commitment to bringing you the lowest
priced prescription medication in the industry. We encourage you to read through this
booklet for more details on how our new initiative can benefit you.
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
generic drugs are low. Of course, U.S. companies have spent billions in advertising to
convince you that brand and generic drugs are not the same in terms of mechanism of
action, although their use is encouraged by AARP.
Statistics
A host of companies are successfully demonstrating India's abilities in chemistry and
manufacturing, and R&D led growth is commonplace.
The Indian pharmaceutical industry has grown exponentially to $5.6 billion USD. It
ranks fifth in terms of volume behind the United States, Japan, Europe, and China
Growth over the last five years has been more than 20%, which is twice the world rate.
Pharmaceutical exports stood at $2.5 billion USD in 2002-2003. Exports to the United
States, which is the world's largest pharmaceutical market, were valued at $450 million
USD.
The Indian pharmaceutical industry has the highest number of production plants
approved by the FDA outside the USA. It also has the largest number of DMFs (drug
master files) filed which gives it access to the high growth generic bulk drugs market.
Generic drug manufacturing is the main growth driver for the future. The world market
is expected to exceed $55 billion USD by 2005. India is set to capture a large portion of
this market by leveraging its inherent strengths in technology, R&D facilities, and trained
human capital.
To facilitate the sector's growth, the Indian government announced exemptions from
import licenses to foreign pharmaceutical units setting up their manufacturing units in
Special Economic Zones.
Setting up a production plant is 40% cheaper in India compared to developed countries.
Therefore, the cost of bulk drug production is 60-70% less.
In accordance with WTO stipulations, India will grant product patent recognition to all
New Chemical Entities beginning in 2005.
GlobalPharmacyMeds.to
Pharmaceutical Exports
R&D Costs
On a scale of 1 - 10, 1 = low, 10 = high
Availability of skilled labor:
Germany
7.5
India
7.4
U.S.
7.2
Brazil
6.4
GlobalPharmacyMeds.to
subsidiaries in all parts of the world. Hexal will invest at least 10 million Euros in the
Indian facility. The company has already entered to partnerships with several Indian
companies."
Not to be outdone, multinationals like Roche, Bayer, Aventis and Chiron, which are
already here, have decided to make India their regional hub for active pharmaceutical
ingredients and supplies of bulk drugs, apart from outsourcing clinical research. Pfizer,
for example, has almost doubled its R&D expenditure in India. Novartis, Astra Zeneca,
Eli Lilly and GlaxoSmithKline, too, are understood to be making India a global hub for
clinical research.
The renewed interest in the Indian market is prompted by the product patents regime
that comes into force in January 2005 - India now recognizes only process patents - and
by low costs.
Says Utkarsh Palnitkar, partner at Ernst & Young, "Innovative pharmaceutical
multinationals, pressured by patent expirations in 2005, the increasing cost of drug
development and declining productivity in R&D, are feeling more confident about
intellectual property rights protection in India and are scaling up their investments."
GlobalPharmacyMeds.to
Cipla Limited
One of the largest drug manufactures, Cipla manufactures and markets bulk drugs and
formulations. It is now ranked second in India by ORG in terms of retail pharmaceutical
sales. All the bulk drug facilities have been approved by the US FDA, and the
formulation facilities have been approved by the Medicine Control Agency, UK; the
Medicine Control Council, South Africa; the Therapeutic Goods Administration,
Australia; and other international agencies.
Cipla has a very wide product range which includes antibiotics, anti-bacterials, antiasthmatics, anti-inflammatory anthelminites, anti-cancer, and cardiovasculars. In
domestic formulation market, antibiotics are the mainstay, and contribute to
approximately 50% of the company's revenue. Some of the leading brands are Ciplox
(Ciprofloxacin), Novamox (Amoxicillin) and Norflox (Norfloxacin). Cipla also has in its
product portfolio Zidovir (zidovudine, anti-AIDS drug). Cipla was one of the first among
the Indian pharmaceutical companies to introduce ampicillin and norfloxacin.
The strength and expansion of Cipla's research and development facilities have
contributed to its role as a leader in new drug formulations. Further, Cipla's ability to
quickly duplicate a new drug introduced elsewhere, and to subsequently inject it into the
Indian market has played a significant role in building a basket of formulation brands.
Being one of the earliest entrants into the market with a new drug, generally, enables a
company to achieve higher realisations. Cipla has exemplified this in its overwhelming
success.
GlobalPharmacyMeds.to
In addition to being among the early entrants, a defining quality of Cipla's strategy is its
ability to market products at a significantly lower price. Cipla has developed the world's
first budesonide-based, chlorofluorocarbons (CFC) free anti-asthma inhaler, 'Budecort
CFC-free'. Budesonide, which falls in the preventive class of anti-asthmatic drugs, is
essentially a steroid and preferred due to its safety profile. The company has invested
over Rs 20 cr in developing CFC-free asthma products over a period of 12 months. The
product is largely being targeted at the international markets, which are CFC-sensitive
and is awaiting for registration in the European markets. The benefits of the new product
will be obtained in the coming years, since the company expects to increase its exports
through this product.
In December 2000, the company cut the price of its anti-AIDS drug Nevimune (scientific
name : nevirapine) by 34% to Rs 650 for a strip of ten tablets. The price was earlier Rs
985. Cipla has slashed the price of the drug thrice reducing it from the launch price of Rs
1,350 for a strip of ten to the current price. The company attributes this to improvements
in technology that has enabled it to cut costs and pass on the savings to consumers.
Website: http://www.cipla.com
GlobalPharmacyMeds.to
as the US and Europe. All this has been possible because of their innovative and
sustained marketing efforts.
Website: http://www.drreddys.com
Lupin Limited
Lupin Limited is one of India's largest manufacturers of bulk actives and formulations.
The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide,
Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The
company also possesses competencies in phytomedicines, in which medicines are made
out of plant and herbal resources supported by the discipline of modern medicine.
Lupin Limited 's world-class manufacturing plants are based in Mandideep (near Bhopal,
Madhya Pradesh), Aurangabad (Maharashtra), Ankleshwar (Gujarat) and Tarapur
(Maharashtra). A number of these facilities have been approved by the USFDA and
UKMCA.
It has established a world-class R&D facility in Pune to spearhead Novel Drug Delivery
Systems (NDDS) and the discovery of New Chemical Entities (NCE).
Lupin Limited strives for global competitiveness in their target segments investing
successfully in innovative strategies, systems, processes and, most importantly, the right
people.
Website: http://www.lupinworld.com/
GlobalPharmacyMeds.to
Important Notice
Trademarks or patents for prescription drug names that appear in this brochure, including,
but not limited to Nexium, Lipitor, Norvasc, Bextra, Avandia, Detrol, Claritin, Zoloft,
Celebrex, Prevacid, Zithromax, Prozac, Paxil, Zocor, Allegra, are the trademark or
copyright property of their respective owners.
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
Aleve
NAPROSYN
Naproxen
RPG Life Sciences Ltd.
Tablet
250mg
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to
5. Your order will be confirmed by one of our customer service representatives and you
will receive a comprehensive invoice by mail shortly thereafter. (ie. You'll get your
invoice BEFORE getting the package with your medications.)
Important Notice
Trademarks or patents for prescription drug names that appear in this brochure, including,
but not limited to Nexium, Lipitor, Norvasc, Bextra, Avandia, Detrol, Claritin, Zoloft,
Celebrex, Prevacid, Zithromax, Prozac, Paxil, Zocor, Allegra, are the trademark or
copyright property of their respective owners.
GlobalPharmacyMeds.to
GlobalPharmacyMeds.to